CAP-2003 represents exosomes isolated from the company’s proprietary cardiosphere-derived cells (CDCs), and is being developed as a next-generation therapeutic platform in regenerative medicine. Exosomes are nano-sized, membrane-enclosed vesicles, or “bubbles” that are secreted by cells and contain bioactive molecules, including proteins, RNAs and microRNAs. They act as messengers to regulate the functions of neighboring cells, and pre-clinical research has shown that exogenously-administered exosomes can direct or, in some cases, re-direct cellular activity, supporting their therapeutic potential. Their size, ease of crossing cell membranes, and ability to communicate in native cellular language makes them an exciting class of potential therapeutic agents. CAP-2003 comprises of exosomes secreted by CDCs, and is believed to mediate many of the effects that are observed with these cells, including anti-inflammatory, pro-angiogenic, anti-apoptotic, and anti-fibrotic effects. Capricor plans to explore development of the exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas.
CSMC has granted Capricor worldwide rights to its CDC Exosome technology under an exclusive license agreement with Cedars-Sinai Medical Center.
View a list of publications relating to Capricor’s exosome technology.